The Biotech Banter crew is getting into the World Cup spirit, looking at foreign biotechs to see whether they're investable.

First up:

Amarin (NASDAQ:AMRN) has a drug on the market, but unfortunately its fish oil Vascepa has struggled to gain much traction. The hope was that the company could get FDA approval for a wider population of patients with moderately high triglyceride levels, but the FDA shot down the idea.

Prosensa (NASDAQ: RNA) is developing a Duchenne muscular dystrophy drug called drisapersen. The drug failed a phase 3 trial, but the company thinks it might still be able to get the drug approved.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is a specialty pharma focused on narcolepsy, oncology, pain, and psychiatry. Shares in the company are up about 125% over the past year, so it must be doing something right.

Watch the following video to see whether senior biotech specialist Brian Orelli and health-care analyst David Williamson give the companies a goal, raise a yellow card, or send them off with a red card.